Transcatheter Heart Valve Replacement Market Size

Transcatheter Heart Valve Replacement Market Size

Transcatheter Heart Valve Replacement Market size valued at over USD 6.2 billion in 2019 and is expected to witness 17.6% CAGR between 2020 and 2026.

Rise in incidences of valvular heart diseases across the globe along with increasing demand for less invasive procedures is propelling the industry growth. Growing geriatric population suffering from heart valve diseases is leading to increase in valve replacement surgeries. Moreover, increasing technological advancements in surgical procedures is augmenting the transcatheter heart valve replacement market demand. Furthermore, favorable reimbursement scenario and growing interest of manufacturers is fostering the market revenue.

To get key market trends

  Download Free Sample

The COVID?19 pandemic has imposed burden on healthcare systems and intensive care unit (ICU) capacity that has led to the suspension of several procedures, including transcatheter aortic valve replacement (TAVR). The postponement of these procedures is associated with irreversible cardiac deterioration of patients or sudden cardiac death and is affecting patients suffering from severe aortic valve stenosis. Thus, the American College of Cardiology (ACC) and Society of Cardiac Angiography and Interventions (SCAI) have established guidelines regarding considerations for patients referred for structural heart disease intervention during the COVID?19 pandemic addressing when to perform TAVR for severe symptomatic aortic stenosis. As a result, even with emergence of second wave of COVID-19, transcatheter heart valve industry will perform strongly in the coming duration.

Increasing prevalence of valvular disease in developing regions of Asia Pacific will drive the transcatheter heart valve replacement market growth. Aortic valvular stenosis or regurgitation caused by rheumatic heart disease or infective endocarditis is becoming prevalent at a rapid pace in developing countries of Asia Pacific. In addition, a major proportion of population in Asia Pacific suffering from rheumatic aortic stenosis comprises of young patients and is recommended to undergo transcatheter valve replacement. As a result, there is an increased demand for transcatheter heart valve replacement products in the region.